{"id":"W2018394017","doi":"10.1007/s10620-010-1504-y","title":"U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for “Difficult-to-Treat” HCV Genotype 1 Patients","year":2011,"lang":"en","type":"article","venue":"Digestive Diseases and Sciences","topic":"Hepatitis C virus research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Veterans Affairs San Diego Healthcare System; Valeant Pharmaceuticals International; Gilead Sciences; Bristol-Myers Squibb","keywords":"Medicine; Ribavirin; Internal medicine; Gastroenterology; Dosing; Hepatology; Viral load; Hepatitis C virus; Pegylated interferon; Alpha interferon; Interferon; Immunology; Virus","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004613801,0.001304837,0.00147661,0.0003830489,0.0009308733,0.0007875658,0.0008164583,0.001155511,0.003216477],"category_scores_gemma":[0.003146646,0.0007522459,0.001220579,0.0003733668,0.001421244,0.001059387,0.0005550896,0.002358802,0.0007426367],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007166297,"about_ca_system_score_gemma":0.002301494,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00157848,"about_ca_topic_score_gemma":0.002480333,"domain_scores_codex":[0.9975476,0.001786038,0.00009580355,0.000215626,0.00009549651,0.0002593798],"domain_scores_gemma":[0.996104,0.0007504376,0.0004120196,0.000251609,0.0002180551,0.002263887],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8438353,0.09460105,0.02554054,0.0001688827,0.0005999421,0.0003539307,0.0003032488,0.000601906,0.008425947,0.0001189558,0.001504995,0.02394521],"study_design_scores_gemma":[0.2880405,0.6842368,0.02526678,0.00001841721,0.0002320784,0.0001880776,0.00008609253,0.0004754665,0.0006802544,0.0000608119,0.000687962,0.0000267862],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975924,0.00024595,0.0001470791,0.0003011097,0.00007074109,0.0009140659,0.0001966898,0.00002061333,0.0005111914],"genre_scores_gemma":[0.9960348,0.0002010171,0.0007815345,0.000681939,0.0002744431,0.001060331,0.0005725413,0.000009391177,0.0003841594],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004613801,"threshold_uncertainty_score":0.02440041,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1062926889444998,"score_gpt":0.3474217838749336,"score_spread":0.2411290949304339,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}